Format
Sort by

Send to

Choose Destination

Search results

Items: 9

1.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators..

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489.

2.

Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.

O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP; SOLID-TIMI 52 Investigators., Steen DL.

JAMA. 2014 Sep 10;312(10):1006-15. doi: 10.1001/jama.2014.11061. Erratum in: JAMA. 2014 Oct 8;312(14):1473. Dylan P. Steen[corrected to Dylan L. Steen].

3.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators..

N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797.

4.

The need for a systematic approach to statin switching: an analysis of real-world experience.

Kakavas PW, McManus JL, Wolfe TA, Guidry T, Flores DN, Ter Riet LB, Glover JJ, Sell H.

J Cardiovasc Nurs. 2013 Nov-Dec;28(6):565-72. doi: 10.1097/JCN.0b013e31826fe89d.

PMID:
23064180
5.

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators..

Am Heart J. 2009 Dec;158(6):896-901.e3. doi: 10.1016/j.ahj.2009.09.017.

PMID:
19958854
6.

Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.

Hoppensteadt D, Fareed J, Klein AL, Jasper SE, Apperson-Hansen C, Lieber EA, Katz WE, Malouf JF, Stoddard MF, Pape LA; Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Investigators..

Am J Cardiol. 2008 Oct 1;102(7):842-6. doi: 10.1016/j.amjcard.2008.05.025.

PMID:
18805108
7.

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.

Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA; Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators..

Lancet. 2008 May 24;371(9626):1761-8. doi: 10.1016/S0140-6736(08)60763-1.

PMID:
18502300
8.

[The cost of treating schizophrenia in Greece].

Geitona M, Ollandezos M, Kousoulakou C, Agelopoulos E, Zaharakis K, Kakavas P, Karpouza B, Kesidou S, Bilanakis N, Papamichael E, Papanicolaou S, Chaidemenos A, Chamogeorgakis T, Kyriopoulos J.

Psychiatriki. 2007 Jan;18(1):47-58. Greek, Modern.

PMID:
22466429
9.

Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function.

Kakavas PW, Ghalie R, Parrillo JE, Kaizer H, Barron JT.

Bone Marrow Transplant. 1995 Jun;15(6):859-61.

PMID:
7581081
Items per page

Supplemental Content

Loading ...
Support Center